Yahoo! Finance Search - Finance Home - Yahoo! - Help

Saturday, September 20 2014 8:08am ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Other
Industry Center > Drug Manufacturers - Other > News
More On This Industry
· Summary
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Drug Manufacturers - Other News
Latest News
Friday, Sep 19, 2014
·Bayer to Shed MaterialScience Business, Shares Rise - Fri 4:10 pm ET
·Weakness Seen in Avanir Pharmaceuticals (AVNR): Stock Falls 6.5% - Fri 6:59 am ET
Thursday, Sep 18, 2014
·OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Thu 4:11 pm ET
·Allergan-Valeant Fight Holds Lessons for All Corporate Shareholders
at The New York Times - Thu 4:05 pm ET
·Valeant's Improving Stock Price Makes its Allergan Bid Look Better
at The Wall Street Journal Online - Thu 1:19 pm ET
·Alexza Pharmaceuticals and Ferrer Provide Update on ADASUVE® European Commercial Activities
PR Newswire - Thu 9:00 am ET
·MEI Pharma To Present At BioCentury's NewsMakers Conference
PR Newswire - Thu 9:00 am ET
·Alcobra (ADHD) Worth Watching: Stock Moves 5.1% Higher - Thu 8:10 am ET
·Tetraphase Pharmaceuticals (TTPH) in Focus: Stocks Up 5.5% - Thu Sep 18
·Novo Nordisk Marks 90 Years of Innovating Diabetes Care
PR Newswire - Thu Sep 18
·Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Business Wire - Thu Sep 18
Wednesday, Sep 17, 2014
·[video] Isis Pharmaceuticals CEO: Not changing name, terrorists can change theirs
at CNBC - Wed Sep 17
·Auxilium Mulls Endo Bid; Is $2.2 Billion Enough?
at Investor's Business Daily, Inc. - Wed Sep 17
·[$$] Auxilium Is Buyable, but Requires Higher Bid
at - Wed Sep 17
·Novo Nordisk's Tresiba Effective in Children & Adolescents - Wed Sep 17
·Endo Looking to Acquire Auxilium Pharmaceuticals for $2.2B - Wed Sep 17
·SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Lannett Company, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of October 27, 2014 -- LCI
GlobeNewswire - Wed Sep 17
·INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Alexza Pharmaceuticals Inc. Regarding Possible Breaches of Fiduciary Duty
PR Newswire - Wed Sep 17
·Valeant’s Last Shot to Woo Owners of Botox Maker Allergan
at The New York Times - Wed Sep 17
·Auxilium Mulls Endo Bid; Street Eyes A Higher Price
at Investor's Business Daily, Inc. - Wed Sep 17
More Latest News...
Sponsor Results
Professional Statistician
All areas of research. Free initial consultation. 877-461-7226
Paperless Reg Docs
Secure online portal for clinical study start-up.
M/A/R/C Research
Designing Customized Solutions Since 1965
(What's This?)

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Other Headlines
More Finance RSS Feeds

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?